Origin
ActiveAI and Data for Cancer Therapeutics
About
Creating the largest patient-derived cancer single-cell dataset for licensing to pharmaceutical and AI companies. These datasets are unique as they screen the effects of various drugs and genetic medicines under the control of our DNA switches.
Founders · 2
CEO @ Origin | Computer Science @ UIUC, Computer Vision and Reinforcement Learning Research, First Prize 2022 OpenCV AI Research Competition.
CTO @ Origin | Prev: Computer Science @ UIUC, ML Research @ Wadhwani AI, Automorphic (YC S23). Published disease modeling research done in high school in Nature Scientific Reports.
Launch
AI designed regulatory DNA sequences to program gene expression patterns
Origin announces Axis, an AI model that designs regulatory DNA sequences to activate therapeutic genes in target disease cell-states, aiming to make cell and gene therapies safer and more effective. They are building a large proprietary dataset of synthetic regulatory elements and claim Axis outperforms Google DeepMind’s AlphaGenome in predictive benchmarks.
Related startups
The agentic drug company. We simulate human biology.
Multimodal foundation models to predict uncollected patient biology
